Literature DB >> 17703109

Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function.

Revekka Harisi1, Jozsef Dudas, Julia Nagy-Olah, Ferenc Timar, Miklos Szendroi, Andras Jeney.   

Abstract

BACKGROUND: Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence. The several chemotherapy-resistant cases of osteosarcoma are at a higher risk of relapse and adverse outcome.
OBJECTIVE: The aim of the current study was to determine the role of extracellular matrix in the resistance developed against chemotherapeutic treatments of human osteosarcoma cells.
MATERIALS AND METHODS: A cell line, named OSCORT was established from the biopsy of a 17-year-old male patient with primary osteosarcoma. Cell proliferation, apoptosis and quantification of DNA damage after treatments with doxorubicin were investigated in classical and three-dimensional cell culture systems using an extracellular matrix gel. The experimental results were related to the clinical observations of the case.
RESULTS: The cells cultured in extracellular matrix gel have shown resistance to doxorubicin similar to that seen in the clinical case, as demonstrated by their proliferation, apoptosis and doxorubicin-induced DNA damage characteristics. Among the extracellular matrix components, the heparan sulfate proteoglycan and-to a lesser extent-fibronectin were involved in the doxorubicin resistance. Laminin and nidogen did not decrease the cytoreductive effect of doxorubicin, while collagen IV even increased it. The extracellular matrix gel decreased the protein levels of p53 and abrogated its cell nuclear translocalization. The most frequent known mutations in the p53 gene were not found in OSCORT cells.
CONCLUSION: The current study provides experimental evidence for an epigenetical, extracellular matrix-induced loss of p53 function, which lead to a potent chemotherapy resistance showing accordance with the clinical experience.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17703109     DOI: 10.4161/cbt.6.8.4443

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.

Authors:  Sunetra Das; Rupa Idate; Daniel P Regan; Jared S Fowles; Susan E Lana; Douglas H Thamm; Daniel L Gustafson; Dawn L Duval
Journal:  Commun Biol       Date:  2021-10-11

Review 2.  Tissue-engineered 3D models for elucidating primary and metastatic bone cancer progression.

Authors:  Eva C González Díaz; Sauradeep Sinha; Raffi S Avedian; Fan Yang
Journal:  Acta Biomater       Date:  2019-08-13       Impact factor: 8.947

3.  Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy.

Authors:  Katja Storch; Nils Cordes
Journal:  Chemother Res Pract       Date:  2012-06-18

Review 4.  Extracellular matrix as target for antitumor therapy.

Authors:  Revekka Harisi; Andras Jeney
Journal:  Onco Targets Ther       Date:  2015-06-09       Impact factor: 4.147

5.  Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicin-resistant uterine cancer.

Authors:  Yi-Wen Lo; Szu-Ting Lin; Shing-Jyh Chang; Chia-Hao Chan; Kevin W Lyu; Jo-Fan Chang; Eugenie Wong Soon May; Dai-Ying Lin; Hsiu-Chuan Chou; Hong-Lin Chan
Journal:  J Cell Mol Med       Date:  2015-01-30       Impact factor: 5.310

6.  Synthesis, antiproliferative activity and molecular properties predictions of galloyl derivatives.

Authors:  Marciane Maximo da Silva; Marina Comin; Thiago Santos Duarte; Mary Ann Foglio; João Ernesto de Carvalho; Maria Carmo do Vieira; Anelise Samara Nazari Formagio
Journal:  Molecules       Date:  2015-03-25       Impact factor: 4.411

7.  Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis.

Authors:  Zhipeng Wang; Shuang Liang; Xin Lian; Lei Liu; Shu Zhao; Qijia Xuan; Li Guo; Hang Liu; Yuguang Yang; Tieying Dong; Yanchen Liu; Zhaoliang Liu; Qingyuan Zhang
Journal:  Sci Rep       Date:  2015-03-30       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.